Filed Pursuant to Rule 424(b)(3)

Registration No. 333-195124

 

PROSPECTUS SUPPLEMENT NO. 1

(To Prospectus dated September 30, 2014)

  

CAN-FITE BIOPHARMA LTD.

 

1,490,378 Ordinary Shares represented by 745,189 American Depositary Shares

 

This Prospectus Supplement No. 1 is required to be delivered by certain holders of the above-referenced shares or by their transferees, pledges, donees or their successors in connection with the offer and sale of the above-referenced shares.

 

This Prospectus Supplement No. 1 supplements the Prospectus dated September 30, 2014 of Can-Fite Biopharma Ltd. (the “Company”), with the following addition and change:

 

  (1) Amend the selling shareholder information set forth in the Prospectus.

 

The attached information modifies and supersedes, in part, the information in the Prospectus. Any information that is modified or superseded in the Prospectus or any amendment or supplement thereto, shall not be deemed to constitute a part of the Prospectus except as modified or superseded by this Prospectus Supplement No. 1. This Prospectus Supplement No. 1 should be read in conjunction with the Prospectus.

 

INVESTING IN OUR SECURITIES INVOLVES A HIGH DEGREE OF RISK. SEE “RISK FACTORS” BEGINNING ON PAGE 7 OF THE PROSPECTUS, AND ANY OF OUR OTHER FILINGS INCORPORATED THEREIN BY REFERENCE.

 

NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR DETERMINED IF THIS PROSPECTUS SUPPLEMENT IS TRUTHFUL OR COMPLETE. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.

 

The date of this Prospectus Supplement is October 2, 2015.

 

 
 

 

AMENDMENT TO SELLING SHAREHOLDER INFORMATION

 

This Prospectus Supplement No. 1 is being filed in connection with changes to the selling shareholders information as set forth in the Prospectus. Specifically, Equitec Specialists, LLC assigned a warrant to purchase 18,204 ordinary shares represented by 9,102 American Depositary Shares, or ADSs, to Intracoastal Capital LLC.

 

As a result, this Prospectus Supplement No. 1 is being filed to amend the selling shareholders table in the Prospectus so that it reflects the changes to such table resulting from the above-described assignments.

 

All other information in the Prospectus shall remain unchanged. Percentage of beneficial ownership was calculated based on 25,454,509 ordinary shares outstanding as of September 30, 2015. This Prospectus Supplement No. 1 reflects only the total number of ordinary shares registered for resale by the subject selling shareholder described herein, and we note that it does not reflect sales of ordinary shares by such selling shareholder pursuant to the Prospectus that may have occurred prior to the date of this Prospectus Supplement No. 1.

 

Selling Shareholder  Number of Ordinary Shares Owned Prior to Offering   Maximum Number of Ordinary Shares to be Sold Pursuant to this Prospectus     Number of Ordinary Shares Owned After the Offering     Percentage of Ordinary Shares Owned After the Offering 
Intracoastal Capital LLC (19)   917,082(20)   18,204(20.1)    898,878(20.2)     3.4%

 

(19)Mitchell P. Kopin, or Mr. Kopin, and Daniel B. Asher, or Mr. Asher, each of whom are managers of Intracoastal Capital LLC, or Intracoastal, have shared voting control and investment discretion over the securities reported herein that are held by Intracoastal. As a result, each of Mr. Kopin and Mr. Asher may be deemed to have beneficial ownership (as determined under Section 13(d) of Exchange Act) of the securities reported herein that are held by Intracoastal.

 

Cranshire Capital Advisors, LLC, or CCA, is the investment manager of Cranshire Capital Master Fund, Ltd., or Cranshire Master Fund, and consequently has voting control and investment discretion over securities held by Cranshire Master Fund described below. Mr. Kopin, the president, the sole member and the sole member of the Board of Managers of CCA, has voting control over CCA. As a result, each of Mr. Kopin and CCA may be deemed to have beneficial ownership (as determined under Section 13(d) of the Exchange Act) of the securities held by Cranshire Master Fund which are described below.

 

In the aggregate, Mr. Kopin may be deemed to have beneficial ownership (as determined under Section 13(d) of the Exchange Act) of 971,694 ordinary shares, which consists of (i) 18,204 ordinary shares represented by 9,102 ADSs issuable upon exercise of warrants originally issued in our March 2014 financing held by Intracoastal, (ii) 898,878 ordinary shares represented by 449,439 ADSs issuable upon exercise of warrants issued in our December 2014 financing held by Intracoastal, and (iii) 54,612 ordinary shares represented by 27,306 ADSs issuable upon exercise of warrants held by Cranshire Master Fund. The foregoing excludes 850,574 ordinary shares represented by 425,287 ADSs issuable upon exercise of warrants issued in our September 2015 financing because the foregoing warrants are not exercisable until on or after March 21, 2016. Without the blocker provision described above with respect to foregoing warrant (and assuming that the foregoing warrant was currently exercisable), Mr. Kopin may be deemed to have beneficial ownership of 1,822,268 represented by 911,134 ADS issuable upon exercise of warrants. Pursuant to the terms of the foregoing warrants the holders cannot exercise such warrants if they would beneficially own, after any such exercise, more than 4.99% of the outstanding ordinary shares.

 

In the aggregate, Mr. Asher may be deemed to have beneficial ownership (as determined under Section 13(d) of the Exchange Act) of 917,082 ordinary shares, which consists of (i) 18,204 ordinary shares represented by 9,102 ADSs issuable upon exercise of warrants originally issued in our March 2014 financing held by Intracoastal, and (ii) 898,878 ordinary shares represented by 449,439 ADSs issuable upon exercise of warrants issued in our December 2014 financing held by Intracoastal. The foregoing excludes 850,574 ordinary shares represented by 425,287 ADSs issuable upon exercise of warrants issued in our September 2015 financing because the foregoing warrants are not exercisable until on or after March 21, 2016. Without the blocker provision described above with respect to foregoing warrant (and assuming that the foregoing warrant was currently exercisable), Mr. Asher may be deemed to have beneficial ownership of 1,767,656 represented by 883,828 ADS issuable upon exercise of warrants. Pursuant to the terms of the foregoing warrants the holders cannot exercise such warrants if they would beneficially own, after any such exercise, more than 4.99% of the outstanding ordinary shares.

 

Mr. Asher, who is a manager of Intracoastal, is also a control person of a broker-dealer. As a result of such common control, Intracoastal may be deemed to be an affiliate of a broker-dealer. Intracoastal acquired the ordinary shares being registered hereunder in the ordinary course of business, and at the time of the acquisition of the ordinary shares and warrants described herein, Intracoastal did not have any arrangements or understandings with any person to distribute such securities.

 

(20)Represents (i) 18,204 ordinary shares represented by 9,102 ADSs issuable upon exercise of warrants originally issued in our March 2014 financing held by Intracoastal, and (ii) 898,878 ordinary shares represented by 449,439 ADSs issuable upon exercise of warrants issued in our December 2014 financing held by Intracoastal.
   
  (20.1) Represents 18,204 ordinary shares represented by 9,102 ADSs issuable upon exercise of warrants originally issued in our March 2014 financing held by Intracoastal.
     
(20.2)Represents 898,878 ordinary shares represented by 449,439 ADSs issuable upon exercise of warrants issued in our December 2014 financing held by Intracoastal.